Evidence map›Paper›PMID 40210794›Full record

ArticleAnnals of biomedical engineering2025

Sustained Release of Antifibrotic Nintedanib from Polymer Microparticles Reduces Dosing Frequency While Reducing Inflammation in Murine Idiopathic Pulmonary Fibrosis.

Emmanuel Einyat Opolot, Filip Goshevski, Rahul Chaudhary, Jessica A Kilgore, Noelle S Williams, Horst A von Recum, Amar B Desai

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of biomedical engineering, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Emmanuel Einyat OpolotDepartment of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, USA.
Filip GoshevskiDepartment of Medicine and Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, USA.
Rahul ChaudharyDepartment of Medicine and Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, USA.
Jessica A KilgoreDepartment of Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Noelle S WilliamsDepartment of Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Horst A von Recum *Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, USA. hav1@case.edu.
Amar B Desai *Department of Medicine and Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, USA. abd10@case.edu.ORCID http://orcid.org/0000-0001-8649-6630

Funding

TUMOR METABOLISM PROGRAMP30CA043703 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI Amar Desai · 1987 to 2026
$142.3M
Clinical and Translational Science Collaborative of Northern Ohio, Catalyzing Linkages to Equity in Health (CLE Health)UM1TR004528 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI GRACE A MCCOMSEY · 2023 to 2026
$32.1M
Clinical and Translational Science Collaborative of Northern Ohio UM1TR004528NCATS NIH HHS UM1 TR004528NCI NIH HHS P30 CA043703NCI NIH HHS P30CA043703
6 · The paper itself

Abstract

purposeIdiopathic pulmonary fibrosis (IPF) is a life-threatening, progressive lung disease with limited therapeutic options, often resulting in poor patient outcomes. Current treatments, such as Nintedanib (NTB) and Pirfenidone (PFD), require frequent administration, leading to adverse effects and low patient adherence. The purpose of this study was to investigate a sustained-release drug delivery system utilizing microparticles (MPs) composed of insoluble beta-cyclodextrin (β-CD) polymers to enhance the bioavailability and extend the release of NTB and PFD.

methodsA multidisciplinary approach, including in silico modeling, in vitro assays, and in vivo studies, was employed to assess the efficacy of β-CD-polymer MPs as drug carriers.

resultsMolecular docking simulations and surface plasmon resonance studies demonstrated a stronger binding affinity of NTB to β-CD-polymer MPs compared to PFD, suggesting an extended delivery profile for NTB over PFD. Pharmacokinetic analysis in healthy mice confirmed sustained-release profiles for both drugs, with NTB maintaining therapeutic plasma concentrations for over 70 h. In a bleomycin-induced IPF mouse model, NTB-loaded β-CD-polymer MPs significantly reduced pro-inflammatory markers and required fewer injections than the standard daily NTB regimen.

conclusionThese findings indicate that β-CD-polymer MPs may serve as a promising platform for reducing dosing frequency of NTB and enhancing therapeutic outcomes in the treatment of IPF.

Indexed as

Antifibrotic Agentsbeta-CyclodextrinsIdiopathic Pulmonary FibrosisIndolesAnimalsDelayed-Action PreparationsDrug CarriersHumansMaleMiceMice, Inbred C57BLMolecular Docking SimulationPyridonesAntifibrotic Agentsbeta-CyclodextrinsbetadexDelayed-Action PreparationsDrug CarriersIndolesnintedanibpirfenidonePyridonesAntifibroticBeta-cyclodextrinIdiopathic pulmonary fibrosisMicroparticlesNintedanibPolymer

Identifiers

PMID40210794
PMCPMC12185609

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.